Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans Jun 4, 2026 07:41AM
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial May 22, 2026 06:50AM
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI Apr 30, 2026 07:00AM
Arch Biopartners raises $600,000 in private placement offering Apr 2, 2026 05:45AM
Arch Biopartners Closes Non-Brokered Private Placement Apr 2, 2026 05:45AM


Mar 30, 2026 06:03AM Arch Biopartners arranges $600,000 private placement at $0.60 per share
Mar 30, 2026 06:03AM Arch Biopartners Arranges Non-Brokered Private Placement
Mar 24, 2026 09:13AM Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
Feb 9, 2026 07:28AM Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Dec 16, 2025 07:40AM Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
Nov 19, 2025 04:28PM Arch Biopartners closes $600,000 private placement
Nov 19, 2025 04:27PM Arch Biopartners Closes Non-Brokered Private Placement
Nov 10, 2025 08:10AM Arch Biopartners arranges $500,000 private placement with company officer
Nov 10, 2025 08:10AM Arch Biopartners Arranges Non-Brokered Private Placement
Nov 5, 2025 08:30AM Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia